Tiziana Life Sciences plc ("Tiziana" or the "Company") Annual General Meeting London, New York, 23 June 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology

York, 23 June 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"),

a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease

in oncology and immunology, today announces that it will hold its annual general meeting ("AGM") on 16 July 2020 at

The Notice of AGM, together with Proxy

Form and the Annual Report and Accounts for the year ended 31 December 2019, will be posted to shareholders today. The Notice

of AGM will shortly also be available on the Company's website: www.tizianalifesciences.com.

Please note that arrangements for the

AGM this year are different from the usual public company in-person format. As we expect significant restrictions on personal

movement to still be in place due to Covid-19, we are utilizing the provisions in our recently adopted articles of association,

which allow for the holding of the meeting virtually, on an electronic platform. Accordingly, this year's AGM will be an

electronic meeting only. All voting at the resolutions at the AGM will be conducted on a poll (a requirement of our recently adopted

articles of association) which means that you should submit your proxy (by post or, preferably, online voting) as soon as possible.

We ask that, where possible, questions which shareholders wish to raise be submitted to info@tizianalifesciences.com in advance.

The platform that we will be using will

allow shareholders the option to submit a separate poll card at the electronic meeting but, to ease administration, we request

that proxies be lodged in advance wherever possible.

Full details of the operation and arrangements for the AGM

are set out in the Notice of AGM.

Sciences plc is a dual listed (NASDAQ: TLSA & UK AIMS: TILS) biotechnology company that focuses on

the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases. In

addition to milciclib, the Company will be shortly initiating phase 2 studies with orally administered foralumab for Crohn's

Disease and nasally administered foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal

antibody (mAb) in clinical development in the world. This phase II compound has potential application in a wide range of autoimmune

and inflammatory diseases, such as Crohn's Disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease

(IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development

of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially

for treatment of COVID-19 patients.